Study of ITU512 for sickle cell disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a new medicine called ITU512 in two groups: healthy volunteers and people with sickle cell disease. In the second part, researchers want to see if ITU512 can help manage sickle cell disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Healthy volunteers: must be between 18 and 55 years old, in good health, and weigh at least 50 kg with a BMI between 18 and 32.
- Healthy volunteers: must be male or female who cannot become pregnant.
- People with sickle cell disease: must have a confirmed diagnosis.
- People with sickle cell disease: cannot be taking hydroxyurea currently.
- Everyone: must not have had a history of heart rhythm problems or certain abnormal heart tests.
- Other study rules may apply.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
This study tests an experimental pill called etavopivat for people with sickle cell disease who have had some pain crises in the past year. The goal is to see if it reduces these crisis episodes.
This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.
This trial tests a “biochip” device using samples from people with sickle cell disease. If it works, it may help doctors study sickle cell biology more accurately using patient samples.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
This trial program studies sickle cell disease and how treatment works, especially for people who are already taking hydroxyurea at a stable, maximum tolerated dose. It may help researchers better understand treatment effects and side effects in real patients.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.